IE48356B1 - Crystalline n-formimidoyl thienamycin - Google Patents
Crystalline n-formimidoyl thienamycinInfo
- Publication number
- IE48356B1 IE48356B1 IE1191/79A IE119179A IE48356B1 IE 48356 B1 IE48356 B1 IE 48356B1 IE 1191/79 A IE1191/79 A IE 1191/79A IE 119179 A IE119179 A IE 119179A IE 48356 B1 IE48356 B1 IE 48356B1
- Authority
- IE
- Ireland
- Prior art keywords
- crystalline
- formimidoyl thienamycin
- thienamycin
- formimidoyl
- monohydrate
- Prior art date
Links
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 title abstract description 10
- -1 N-formimidoyl thienamycin monohydrate Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000013078 crystal Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WIESNNVNXBYTFK-FLIBITNWSA-N (z)-2-[(2,2-dimethylcyclopropanecarbonyl)amino]oct-2-enoic acid Chemical compound CCCCC\C=C(C(O)=O)/NC(=O)C1CC1(C)C WIESNNVNXBYTFK-FLIBITNWSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229910016523 CuKa Inorganic materials 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WKDDRNSBRWANNC-ATRFCDNQSA-N Thienamycin Chemical compound C1C(SCCN)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 WKDDRNSBRWANNC-ATRFCDNQSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229940090955 Dipeptidase inhibitor Drugs 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 241001245789 Goodea atripinnis Species 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92137978A | 1978-07-03 | 1978-07-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE791191L IE791191L (en) | 1980-01-03 |
| IE48356B1 true IE48356B1 (en) | 1984-12-26 |
Family
ID=25445341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1191/79A IE48356B1 (en) | 1978-07-03 | 1979-08-08 | Crystalline n-formimidoyl thienamycin |
Country Status (6)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR70784B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1979-11-02 | 1983-03-23 | Merck & Co Inc | |
| US4374772A (en) * | 1981-03-19 | 1983-02-22 | Merck & Co., Inc. | Process for the preparation of N-formimidoyl thienamycin and reagents therefor |
| US4713451A (en) * | 1984-04-09 | 1987-12-15 | Merck & Co., Inc. | Crystalline dimethyliminothienamycin |
| JPS61207617A (ja) * | 1985-03-05 | 1986-09-16 | Toyobo Co Ltd | ポリエステル繊維の製造方法 |
| IE60588B1 (en) * | 1986-07-30 | 1994-07-27 | Sumitomo Pharma | Carbapenem compound in crystalline form, and its production and use |
| DK168047B1 (da) * | 1987-12-07 | 1994-01-24 | Lederle Japan Ltd | (1r,5s,6s)-2-substitueret thio-6-oe(r)-1-hydroxyethylaa-1-methyl-carbapenem-3-carboxylsyrederivater, fremgangsmaade til remstilling deraf, midler og praeparater indeholdende den krystallinske forbindelse samt dens anvendelse. |
| US5317016A (en) * | 1991-08-20 | 1994-05-31 | Shionogi Seiyaku Kabushiki Kaisha | Pyrrolidylthiocarbapenem derivative |
| EA200400682A1 (ru) | 2001-11-16 | 2004-10-28 | Рэнбакси Лабораториз Лимитед | Способ получения кристаллического имипенема |
| CN100497338C (zh) * | 2006-01-05 | 2009-06-10 | 上海医药工业研究院 | 4－甲基－7－氧－1－氮杂双环[3.2.0]庚－2－烯－2－羧酸类衍生物的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE848545A (fr) * | 1975-11-21 | 1977-05-20 | Derives n-methylene substitues de thienamycine, | |
| AU512383B2 (en) * | 1975-11-21 | 1980-10-09 | Merck & Co., Inc. | Thinenamycin derivatives |
-
1979
- 1979-07-02 DK DK278879A patent/DK153486C/da active
- 1979-07-03 DE DE7979102240T patent/DE2963882D1/de not_active Expired
- 1979-07-03 JP JP8357379A patent/JPS559090A/ja active Granted
- 1979-07-03 EP EP79102240A patent/EP0006639B1/en not_active Expired
- 1979-07-03 AT AT79102240T patent/ATE1676T1/de active
- 1979-08-08 IE IE1191/79A patent/IE48356B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK153486C (da) | 1988-11-28 |
| EP0006639B1 (en) | 1982-10-20 |
| EP0006639A1 (en) | 1980-01-09 |
| DK153486B (da) | 1988-07-18 |
| JPS559090A (en) | 1980-01-22 |
| ATE1676T1 (de) | 1982-11-15 |
| DE2963882D1 (en) | 1982-11-25 |
| DK278879A (da) | 1980-01-04 |
| IE791191L (en) | 1980-01-03 |
| JPH0248557B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4260543A (en) | Crystalline N-formimidoyl thienamycin | |
| KR100344479B1 (ko) | 카바페넴항생물질을안정화시키는방법 | |
| DE69425131T2 (de) | Verwendung von clavulansäure und einem antibiotikum zur behandlung von infektionen | |
| IE861984L (en) | Crystalline salt of guanine derivative | |
| US5859238A (en) | Alkylenediammonium diclavulanate derivatives, a process for the preparation thereof as well as the use thereof | |
| EP0006639B1 (en) | Crystalline n-formimidoyl thienamycin | |
| FR2528847A1 (fr) | Produits nouveaux de la classe des carbapenems et leur application en tant qu'antibiotiques | |
| US5952323A (en) | Carbapenem antibiotic | |
| CH640236A5 (en) | 3-(2-Aminoethylthio)-6-ethyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2 -carboxylic acid and process for its preparation | |
| EP0178911B1 (en) | Composition containing a penem or carbapenem antibiotic | |
| EP0133096B1 (fr) | Nouveaux dérivés de synergistines, leur préparation et les compositions pharmaceutiques qui les contiennent | |
| LU86678A1 (fr) | Carbapenemes portant en position 2 un substituant heterothioalcoylthio quaternise | |
| EP0235823A2 (en) | Carbapenem antibiotics, a process for preparing them and pharmaceutical compositions containing them | |
| EP0369503B1 (en) | Method for the control of pneumocystis carinii | |
| US3474089A (en) | Substituted adamantyl penicillins | |
| EP0548790B1 (de) | (1'S)-Hydroxyalkyloxapenem-3-carbonsäuren und ihre Verwendung als Betalactamasehemmer | |
| IE781858L (en) | N-methylene thienamycin derivatives | |
| EP0046596B1 (en) | Antibiotic pa-39504-x3, process for its production and pharmaceutical compositions | |
| US4341791A (en) | 6-, 2- and 1,1-Disubstituted-1-carbadethiapen-2-em-3-carboxylic acid S-oxides | |
| US20020004595A1 (en) | Process for preparing potassium clavulanate | |
| JPS6187682A (ja) | カルバペネム抗生物質 | |
| EP0880966A1 (en) | Thiamine disulfides and medicines containing the same as the active ingredient | |
| EP0161843A1 (en) | New salts of fosfomycin with imidazole | |
| US4409207A (en) | Derivatives of clavulanic acid, a process for their preparation and their use | |
| GB2157565A (en) | Synergistic antibiotic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |